MS Canada Joins Global Efforts on World MS Day to Foster Connection and Advance MS Research and Awareness
TORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- MS Canada, the country’s leading organization in multiple sclerosis (MS) research and advocacy...
Disability
Thousands of Canadians Coast to Coast Walk Together In Support of Those Affected by Multiple Sclerosis
TORONTO, May 24, 2023 (GLOBE NEWSWIRE) -- On May 28, Canadians coast to coast will come together to take part...
Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT
New OTL-203 proof-of-concept data demonstrate extensive metabolic correction in the skeletal system of patients with MPS-IH including normal growth rates,...
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update Capital Markets Day held in April highlighted...
Relievant Medsystems Announces More Than 10,000 Patients Treated with the Intracept® Procedure for Vertebrogenic Low Back Pain
MINNEAPOLIS, May 09, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic...
Pathways to Cures are in Sight as MS Canada Hosts Annual Day on the Hill with Carnation Pinning
OTTAWA, May 01, 2023 (GLOBE NEWSWIRE) -- Dozens of representatives of MS Canada are fanning across Ottawa May 1st – May...
TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
First quarter 2023 BRIUMVI net sales of $7.8 million Over 400 BRIUMVI prescriptions in the first partial quarter from 165+...
Clinical Study Shows 92% of Patients Report Resolution of Migraine Headaches Using Vivos’ POD® Appliance Treatment
Study Data Highlights New Vivos Treatment Option is Highly Effective in Treating Migraine Headaches, One of the World’s Most Common...
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meeting
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I...
Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights...
IntelGenx Announces FDA Approval of RIZAFILM® for the Treatment of Acute Migraine
Partner Gensco® Pharma preparing to commercially launch RIZAFILM® across the United States as soon as is practicableSAINT LAURENT, Quebec, April...
CloudMD Names Dhruv Chandra Chief Technology Officer to Accelerate Technological Advancement in Next Phase of Growth
CloudMD strengthens its commitment to innovation, exceptional customer experiences, data-driven insights, security, and complianceVANCOUVER, British Columbia, April 10, 2023 (GLOBE...
The Hazelden Betty Ford Foundation and TELUS Health collaborate to expand substance use disorder treatment and mental health support
CENTER CITY, Minn. and VANCOUVER, British Columbia, April 05, 2023 (GLOBE NEWSWIRE) -- The Hazelden Betty Ford Foundation and TELUS...
Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
MELBOURNE, Australia and SAN FRANCISCO, April 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
NEW YORK, March 31, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the Committee for Medicinal Products for Human...
electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury
Pre-clinical trial demonstrates the ability of nVNS to decrease the amount of brain injury, decrease anxiety and improve motor function...
GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray
New research released at ACMG Annual Clinical Genetics Meeting reiterates the superiority of exome sequencing’s role in shortening the diagnostic...
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
MELBOURNE, Australia and SAN FRANCISCO, March 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),...
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘UPLIFT’ Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD)
Results from Planned Interim Analysis Expected Fourth Quarter 2023 Approximately 21 Million Adults in U.S. Suffer From a Major Depressive...
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting
NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data...